Akèy › Kansè renn (Kasinom selil renn) › Massachusetts
Etid klinik pou Kansè renn (Kasinom selil renn) nan Massachusetts
18 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05536141Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Massachusetts General Hospital Cancer Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07227415Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Beverly Hospital, Beverly
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- ak 7 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06661720A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07123090Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06966024A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07195682A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT03972657Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Lahey Hospital and Medical Center, Burlington
- Lahey Medical Center-Peabody, Peabody
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT07383441KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04777994Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06053658Drug Screening Using Novel IMD in Renal Cell Carcinoma
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT05700461Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT07397611Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT04787042Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.